… in the Department of Medical Oncology & … guidelines for second-line treatments, while emphasizing the … , pazopanib [Votrient], sunitinib [Sutent], bevacizumab [Avastin], etc, … pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer …

… Sarcoma Unit and a medical oncologist at The Royal … , randomized phase 3 IMADGIST trial. IMADGIST evaluated maintenance imatinib … 2 randomized trials which will hopefully guide treatment in the … receive ripretinib or sunitinib [Sutent]. The primary end point …

… features, biologies, and treatment responses. nccRCC histologies include … excluded from RCC clinical trials, which mainly enrolled … led investigator-initiated randomized trial, patients with untreated … TKI) monotherapy with sunitinib (Sutent). The study met its …

… care while on clinical trials because we are actively … tolerability, effectiveness of the drugs, and how long patients … effects, hold the medication, and then resume treatment. As for tumor … Sutent (sunitinib). This is the STELLAR-304 study, a large trial …

… a consultant medical oncologist, professor of medical oncology, and … in the evolving treatment landscape for patients with … recently completed trials. The phase 3 INSIGHT trial (NCT05734105) … (Qinlock) or sunitinib (Sutent), with progression-free survival …

… trial (NCT03673501) comparing ripretinib (Qinlock) and sunitinib malate (Sutent) … 3/4 drug-related TEAEs (27% v … on ripretinib and sunitinib treatment, respectively. Consistent … treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial …

… director of Clinical Trials, Breast Oncology; and … professor of medicine at Harvard Medical School, previously … drug conjugates, and targeted therapies, we are not only providing better treatments … ;ipilimumab vs sunitinib (Sutent). However, clinical outcomes …

… the regional medical oncology lead for … trial did end up leading to FDA approval [of adjuvant sunitinib (Sutent … trials evaluating adjuvant treatment strategies] should be a TKI because of the FDA … drug effect alone. Of these 4 trials, we have 1 positive trial …

… associate professor of medicine at Harvard Medical School, both … pNETs, sunitinib [Sutent] is an FDA approved option. However … pause treatment or reduce the dose. In the trial, … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves- …

… biomarker could help inform treatment selection in the frontline … and director of Genitourinary Medical Oncology Research in New … ] phase 3 KEYNOTE-426 trial [NCT02853331], pembrolizumab [Keytruda] … was compared against sunitinib [Sutent] monotherapy, which was …